Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Medtronic
Harvard Business School
Express Scripts

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Patent: 9,999,655

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,999,655
Title:Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
Abstract: Pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells are described. In some aspects, administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.
Inventor(s): Lander; Cynthia (Mendham, NJ), Brophy; Colleen (Nashville, TN), Peterson; Caryn (Encinitas, CA), Luber; Andrew (Voorhees, NJ)
Assignee: Moerae Matrix, Inc. (Morristown, NJ)
Application Number:15/066,976
Patent Claims:see list of patent claims

Details for Patent 9,999,655

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Moerae Matrix, Inc. (Morristown, NJ) 2035-03-12 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Moerae Matrix, Inc. (Morristown, NJ) 2035-03-12 RX Orphan search
Eli Lilly And Co CYRAMZA ramucirumab INJECTABLE;INJECTION 125477 001 2014-04-21   Start Trial Moerae Matrix, Inc. (Morristown, NJ) 2035-03-12 RX search
Eli Lilly And Co CYRAMZA ramucirumab INJECTABLE;INJECTION 125477 002 2014-04-21   Start Trial Moerae Matrix, Inc. (Morristown, NJ) 2035-03-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Colorcon
Express Scripts
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.